Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations

Triamcinolone acetonide (TA) is a glucocorticoid (GC) widely used in sports medicine. GCs are prohibited in sports competitions by oral, intramuscular (IM), intravenous and rectal administrations, and they are allowed by other routes considered of local action such as intranasal administration (INT)...

Descripción completa

Detalles Bibliográficos
Autores: Coll Camenforte, Sergi, 1991-, Monfort Mercader, Núria, 1983-, Alechaga, Élida, Matabosch Geronès, Xavier, Pérez Mañá, Clara, Ventura Alemany, Rosa
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2019
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/44345
Acceso en línea:http://hdl.handle.net/10230/44345
http://dx.doi.org/10.1016/j.steroids.2019.108464
Access Level:acceso abierto
Palabra clave:Administration routes
Anti-doping
Metabolism
Triamcinolone acetonide
id ES_fe498e39e4ece83cd3629389ac90c322
oai_identifier_str oai:repositori.upf.edu:10230/44345
network_acronym_str ES
network_name_str España
repository_id_str
spelling Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrationsColl Camenforte, Sergi, 1991-Monfort Mercader, Núria, 1983-Alechaga, ÉlidaMatabosch Geronès, XavierPérez Mañá, ClaraVentura Alemany, RosaAdministration routesAnti-dopingMetabolismTriamcinolone acetonideTriamcinolone acetonide (TA) is a glucocorticoid (GC) widely used in sports medicine. GCs are prohibited in sports competitions by oral, intramuscular (IM), intravenous and rectal administrations, and they are allowed by other routes considered of local action such as intranasal administration (INT). We examined the urinary profiles of TA and its metabolites after INT and high-dose IM administrations. We also measured concentrations of TA and cortisol (CORT) in plasma following IM administration. TA was administered to healthy volunteers using INT route (220 μg/day for 3 days, n = 4 males and 4 females) or IM route (single dose of 40 mg, n = 4 males and 4 females and single dose 80 mg, n = 4 males). Urine and plasma samples were collected before and after administration at different time periods, and were analysed by liquid chromatography-tandem mass spectrometry. TA concentrations in urine were constant during 23 days after IM injection (range 1.4-129.0 ng/mL), and were very low after INT administration (range 0.0-3.5 ng/mL). For 6β-hydroxy-triamcinolone, the main TA metabolite, higher concentrations were detected (0.0-93.7 ng/mL and 15.7-973.9 ng/mL after INT and IM administrations, respectively). On the other hand, TA was detected in all plasma samples collected during 23 days after IM administration (range 0.2-5.7 ng/mL). CORT levels were largely suppressed after IM injection, and were recovered in a dose-dependent manner. In view of the results obtained, we propose a reporting level of 5 ng/mL for TA to distinguish forbidden from allowed TA administrations in sports. We also suggest that other GCs with faster urinary elimination from the body should be considered for IM therapies in out-of-competition rather than TA, in order to reduce the possibility of reporting false adverse analytical findings.Elsevier20202019info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/44345http://dx.doi.org/10.1016/j.steroids.2019.108464reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésSteroids. 2019 Nov;151:108464© Elsevier http://dx.doi.org/10.1016/j.steroids.2019.108464info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/443452026-06-12T07:21:37Z
dc.title.none.fl_str_mv Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
title Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
spellingShingle Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
Coll Camenforte, Sergi, 1991-
Administration routes
Anti-doping
Metabolism
Triamcinolone acetonide
title_short Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
title_full Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
title_fullStr Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
title_full_unstemmed Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
title_sort Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations
dc.creator.none.fl_str_mv Coll Camenforte, Sergi, 1991-
Monfort Mercader, Núria, 1983-
Alechaga, Élida
Matabosch Geronès, Xavier
Pérez Mañá, Clara
Ventura Alemany, Rosa
author Coll Camenforte, Sergi, 1991-
author_facet Coll Camenforte, Sergi, 1991-
Monfort Mercader, Núria, 1983-
Alechaga, Élida
Matabosch Geronès, Xavier
Pérez Mañá, Clara
Ventura Alemany, Rosa
author_role author
author2 Monfort Mercader, Núria, 1983-
Alechaga, Élida
Matabosch Geronès, Xavier
Pérez Mañá, Clara
Ventura Alemany, Rosa
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Administration routes
Anti-doping
Metabolism
Triamcinolone acetonide
topic Administration routes
Anti-doping
Metabolism
Triamcinolone acetonide
description Triamcinolone acetonide (TA) is a glucocorticoid (GC) widely used in sports medicine. GCs are prohibited in sports competitions by oral, intramuscular (IM), intravenous and rectal administrations, and they are allowed by other routes considered of local action such as intranasal administration (INT). We examined the urinary profiles of TA and its metabolites after INT and high-dose IM administrations. We also measured concentrations of TA and cortisol (CORT) in plasma following IM administration. TA was administered to healthy volunteers using INT route (220 μg/day for 3 days, n = 4 males and 4 females) or IM route (single dose of 40 mg, n = 4 males and 4 females and single dose 80 mg, n = 4 males). Urine and plasma samples were collected before and after administration at different time periods, and were analysed by liquid chromatography-tandem mass spectrometry. TA concentrations in urine were constant during 23 days after IM injection (range 1.4-129.0 ng/mL), and were very low after INT administration (range 0.0-3.5 ng/mL). For 6β-hydroxy-triamcinolone, the main TA metabolite, higher concentrations were detected (0.0-93.7 ng/mL and 15.7-973.9 ng/mL after INT and IM administrations, respectively). On the other hand, TA was detected in all plasma samples collected during 23 days after IM administration (range 0.2-5.7 ng/mL). CORT levels were largely suppressed after IM injection, and were recovered in a dose-dependent manner. In view of the results obtained, we propose a reporting level of 5 ng/mL for TA to distinguish forbidden from allowed TA administrations in sports. We also suggest that other GCs with faster urinary elimination from the body should be considered for IM therapies in out-of-competition rather than TA, in order to reduce the possibility of reporting false adverse analytical findings.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/44345
http://dx.doi.org/10.1016/j.steroids.2019.108464
url http://hdl.handle.net/10230/44345
http://dx.doi.org/10.1016/j.steroids.2019.108464
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Steroids. 2019 Nov;151:108464
dc.rights.none.fl_str_mv © Elsevier http://dx.doi.org/10.1016/j.steroids.2019.108464
info:eu-repo/semantics/openAccess
rights_invalid_str_mv © Elsevier http://dx.doi.org/10.1016/j.steroids.2019.108464
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425671551320064
score 15.812455

Similares en LA Referencia